Abbaspour Mohammadreza, Sadooghi Asieh, Khodaverdi Elham, Shahdadi Sardou Hossein, Nokhodchi Ali
Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Bioimpacts. 2024 Jul 8;15:30098. doi: 10.34172/bi.30098. eCollection 2025.
This study aimed to investigate the feasibility of preparation of sustained-release chlorpheniramine maleate (CPM) pellets based on Compritol® as a lipid matrix and evaluation of the affecting factors on pellet properties.
Using the D-optimal experimental design, different pellet formulations containing various amounts of CPM, Compritol® and Avicel were prepared by the wet extrusion-spheronization method. Then the pellets were cured at 40, 65 and 90 °C for 4 and 8 h to study the effect of the thermal process. The physicomechanical properties of the pellets were investigated in terms of particle size distribution, pelletization yield, mechanical strength, aspect ratio and sphericity. To investigate the possible interaction of CPM and Compritol®, as well as to evaluate the morphology and surface characteristics of the pellets DSC and SEM were used, respectively. Also, to investigate the drug release rate from pellets the dissolution test was carried out and mean dissolution time (MDT) was calculated to compare different formulations.
The results showed that the curing process up to 65 °C improves the strength of the pellets. However, increasing the curing temperature from 65 to 90 °C and also increasing the curing time from 4 to 8 h did not have a significant effect on the strength of the pellets but increased the drug release rate of pellets. Increasing the amount of the drug or decreasing Compritol® in the matrix of pellets leads to a larger particle size with greater mechanical strength. All formulations of the pellets had an aspect ratio and sphericity of about 1.1 and 0.9 respectively, which indicates the spherical shape of the pellets as shown by SEM. DSC thermograms indicate the reduction of the crystallinity or the change of the crystalline form of the drug to amorphous during the pelletization process.
The results revealed the feasibility of preparing lipid-based sustained-release matrix pellets using the wet extrusion-spheronization method. The optimal formulation in terms of physicomechanical properties and release rate was the formulation containing 8% CPM, 67% Compritol® and 25% Avicel, which were dried at 40 ° C for 4 h and released about 90% of the drug within 12 h.
本研究旨在探讨以Compritol®为脂质基质制备马来酸氯苯那敏(CPM)缓释微丸的可行性,并评估影响微丸性质的因素。
采用D-最优实验设计,通过湿法制粒挤出滚圆法制备含有不同量CPM、Compritol®和微晶纤维素的不同微丸制剂。然后将微丸在40、65和90℃下固化4小时和8小时,以研究热过程的影响。从粒径分布、制丸收率、机械强度、长径比和球形度等方面研究微丸的物理机械性能。分别采用差示扫描量热法(DSC)和扫描电子显微镜(SEM)研究CPM与Compritol®之间可能的相互作用,以及评估微丸的形态和表面特征。此外,通过进行溶出试验研究微丸的药物释放速率,并计算平均溶出时间(MDT)以比较不同制剂。
结果表明,在65℃以下的固化过程可提高微丸强度。然而,将固化温度从65℃提高到90℃以及将固化时间从4小时增加到8小时,对微丸强度没有显著影响,但会提高微丸的药物释放速率。增加药物量或减少微丸基质中的Compritol®会导致粒径更大且机械强度更高。所有微丸制剂的长径比和球形度分别约为1.1和0.9,这表明SEM显示微丸呈球形。DSC热谱图表明在制丸过程中药物的结晶度降低或晶型转变为无定形。
结果揭示了采用湿法制粒挤出滚圆法制备脂质基缓释基质微丸的可行性。就物理机械性能和释放速率而言,最佳制剂是含有8% CPM、67% Compritol®和25%微晶纤维素的制剂,该制剂在40℃下干燥4小时,并在12小时内释放约90%的药物。